LLY

1,068.18

-0.55%↓

JNJ

223.34

+0.54%↑

ABBV

213.21

+0.63%↑

UNH

375.03

-0.89%↓

MRK

116.08

+1.27%↑

LLY

1,068.18

-0.55%↓

JNJ

223.34

+0.54%↑

ABBV

213.21

+0.63%↑

UNH

375.03

-0.89%↓

MRK

116.08

+1.27%↑

LLY

1,068.18

-0.55%↓

JNJ

223.34

+0.54%↑

ABBV

213.21

+0.63%↑

UNH

375.03

-0.89%↓

MRK

116.08

+1.27%↑

LLY

1,068.18

-0.55%↓

JNJ

223.34

+0.54%↑

ABBV

213.21

+0.63%↑

UNH

375.03

-0.89%↓

MRK

116.08

+1.27%↑

LLY

1,068.18

-0.55%↓

JNJ

223.34

+0.54%↑

ABBV

213.21

+0.63%↑

UNH

375.03

-0.89%↓

MRK

116.08

+1.27%↑

Home・Stock List・Codexis Inc

Codexis Inc

Open

SectorHealthcare

2.69 -1.1

Buy Sell

Overview

Share price change

24h

Current

Min

2.61

Max

2.7199999999999998

Key metrics
By Trading Economics
Income	-18M -8.7M
Sales	-24M 15M
EPS	-0.1
Profit margin	-57.083
Employees	146
EBITDA	-23M -5.8M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+158.43% upside

Dividends
By Dow Jones
Next Earnings	12 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-1.8M 226M
Previous open	3.79
Previous close	2.69

News Sentiment

By Acuity

50%

153 / 344 Healthcare

Codexis Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Nov 2025, 21:37 UTC

Earnings

Codexis to Cut About 24% of Workforce

Peer Comparison

Price change

Codexis Inc Forecast

Price Target

By TipRanks

158.43% upside

12 Months Forecast

Average 6.9 USD 158.43%

High 11 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forCodexis Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Codexis Inc - Dist in the past 3 months.

Sentiment

By Acuity

153 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.